PCN90 Cost Effectiveness Analysis of Bendamustine as First Line Treatment for Chronic Lymphocytic Leukaemia in the Netherlands
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.2130
https://www.valueinhealthjournal.com/article/S1098-3015(12)03844-2/fulltext
Title :
PCN90 Cost Effectiveness Analysis of Bendamustine as First Line Treatment for Chronic Lymphocytic Leukaemia in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03844-2&doi=10.1016/j.jval.2012.08.2130
First page :
A425
Section Title :
Cancer
Open access? :
No
Section Order :
781